Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanislas Ropert

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
BJU International|August 13, 2018
Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancerCharlotte Fenioux, Christophe Louvet, Emilie Charton, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 17, 2020
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018Florian Guisier, Catherine Dubos-Arvis, Florent Viñas, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 23, 2008
Netrin-4 inhibits angiogenesis via binding to neogenin and recruitment of Unc5BEsma Lejmi, Laurence Leconte, Sandrine Pédron-Mazoyer, et al.
Cancer Medicine|August 16, 2022
Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: A multicenter, retrospective studySarah Watson, Benjamin Verret, Stanislas Ropert, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
BJU International|August 13, 2018
Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancerCharlotte Fenioux, Christophe Louvet, Emilie Charton, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 17, 2020
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018Florian Guisier, Catherine Dubos-Arvis, Florent Viñas, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 23, 2008
Netrin-4 inhibits angiogenesis via binding to neogenin and recruitment of Unc5BEsma Lejmi, Laurence Leconte, Sandrine Pédron-Mazoyer, et al.
Cancer Medicine|August 16, 2022
Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: A multicenter, retrospective studySarah Watson, Benjamin Verret, Stanislas Ropert, et al.
Pageof 6